MedPath

Comparison of tamsulosin vs. tamsulosin plus mirabegron in the management of overactive bladder in men with lower urinary tract symptoms

Phase 4
Conditions
Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Registration Number
CTRI/2022/09/045280
Lead Sponsor
Dr Harmandeep Singh Chahal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

newly diagnosed uncomplicated BPE of any size with predominant OABSS and an IPSS >7 without any medical contraindications to planned drug therapy or any absolute indication for surgery

Exclusion Criteria

history of anaphylaxis/ hypersensitivity, drug therapy with metabolic interference to administered medication, prostatic/urethral surgery and other concomitant prostate disease/ cancers, clinical neurological disorders and or neurogenic bladder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
improvement in OABSSTimepoint: Day 0; <br/ ><br>After 8 weeks
Secondary Outcome Measures
NameTimeMethod
improvement in IPSSTimepoint: Day 0; <br/ ><br>After 8 weeks
© Copyright 2025. All Rights Reserved by MedPath